GSE210205
Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy
The aim of this study is to construct an inflammatory response-related genes (IRRGs) signature to monitor biochemical recurrence (BCR) and treatment effects in prostate cancer patients (PCa) Overall design: We applied RNA-seq to screen out the differentially expressed genes (DEGs) between the benign prostate cell line and the PCa cell line, including 4 of BPH-1, 4 of DU145, and 4 of PC3